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Introduction: A subset of non–small-cell lung cancer (NSCLC) 
patients with malignant pleural effusion and/or malignant pleural 
nodules is now classified as stage IV and is generally considered a 
contraindication to surgery. However, several reports have demon-
strated that the prognosis of patients with pleural carcinomatosis 
first detected at thoracotomy is relatively favorable. The aim of this 
study was to describe the results of surgical intervention in NSCLC 
patients with pleural carcinomatosis in Japan.
Methods: In 2010, the Japanese Joint Committee of Lung Cancer 
Registry conducted a nationwide registration of lung cancer patients 
who underwent surgery in 2004. Using this database, we performed a 
retrospective study focused on pleural carcinomatosis. We examined 
the clinicopathological features, the current status of therapy, and 
surgical outcomes in patients with pleural carcinomatosis.
Results: Among the 11,420 registered NSCLC patients, 329 (2.9%) 
patients had pleural carcinomatosis. The median survival time and 
5-year survival rate of 313 patients without other metastatic disease 
were 34.0 months and 29.3%, respectively. Primary tumor resection was 
performed in 256 (81.8%) patients, and macroscopic complete resec-
tion was achieved in 152 (48.6%) patients, with 5-year survival rates 
of 33.1% and 37.1%, respectively. Multivariate analysis revealed that 
Eastern Cooperative Oncology Group performance status (p < 0.001), 
best stage nodal status (p = 0.002), and the presence or absence of gross 
residual tumor (p = 0.013) were independent predictors of survival.
Conclusion: In our surgical registry for NSCLC, patients with pleu-
ral carcinomatosis accounted for 2.9%, and macroscopic complete 
resection for them was associated with better survival.
Key Words: Non–small-cell lung cancer, Pleural carcinomatosis, 
Malignant pleural effusion, Malignant pleural nodule, Surgical treatment.
(J Thorac Oncol. 2015;10: 1076–1082)
Pleural carcinomatosis is defined as the progression of the primary cancer to the pleural cavity.1 In particular, 
it includes malignant pleural effusion (MPE) and/or malig-
nant pleural nodules (MPN). Generally, non–small-cell lung 
cancer (NSCLC) patients with pleural carcinomatosis have a 
poor prognosis and are considered unsuitable candidates for 
surgery.2–4 In the 7th edition of the tumor, node, metastasis 
(TNM) staging system for lung cancer, pleural carcinomato-
sis was reclassified from T4 to M1a.5 However, patients with 
pleural carcinomatosis are very diverse; some have minimal 
amounts of pleural effusion, which is only detected at thora-
cotomy, and others have massive amounts of pleural effusion 
and symptoms. In fact, a number of papers have reported that 
the postoperative prognosis of patients diagnosed with malig-
nant pleural disease at thoracotomy is relatively favorable.6–11
Herein, we aimed to describe the results of surgical 
intervention in NSCLC patients with pleural carcinomatosis 
in Japan during 2004.
PATIENTS AND METHODS
Patients
In 2010, the Japanese Joint Committee of Lung Cancer 
Registry conducted a nationwide registration of lung cancer 
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patients who underwent surgery in 2004. As described previ-
ously, the committee asked the 605 teaching hospitals certified 
by the Japanese Board of General Thoracic Surgery to join 
the study, of which 253 (41.8%) participated.12 From these 
institutions, clinicopathological data and survival outcomes 
for 11,663 patients were collected. This registry was approved 
by the institutional review board of Osaka University Medical 
Hospital where the registry office is located.
In the registry, the total number of patients with NSCLC 
was 11,420, but 45 patients had incomplete pleural carcino-
matosis data. Thus, we ultimately analyzed 11,375 patients in 
this study. The TNM staging was reclassified according to the 
7th edition of the International Union Against Cancer-TNM 
staging system published in 2009.13 Patients did not always 
have pathological stage records, so we adopted the concept of 
best stage, which is defined as the pathological stage if avail-
able and clinical otherwise.5 Although, as for pleural carcino-
matosis, we selected patients with cytologically proven MPE 
and/or histologically proven MPN.
Statistical Analysis
We examined the clinicopathological features, the cur-
rent status of therapy, and survival outcomes in patients with 
pleural carcinomatosis. Fisher’s exact test or χ2 test for cat-
egorical data and t-test for continuous data were used to com-
pare differences in clinicopathological variables and treatment 
modalities. Overall survival was calculated from the date of 
surgery to the date of last follow-up or death. Survival curves 
were estimated using the Kaplan–Meier method and com-
pared using the log-rank test. Univariate and multivariate Cox 
proportional hazards models were used to identify prognostic 
factors after surgery. A significant difference was defined as 
a p value less than 0.05. Statistical analyses were performed 
with SPSS 19.0 (IBM Corp, Armonk, NY) and the SAS 9.3 
(SAS institute, Inc, Cary, NC).
RESULTS
There were 329 (2.9%) patients with pleural carcinoma-
tosis. Of these patients, 183 had MPE (98 with MPN, 82 with-
out MPN, and 3 with unknown data for MPN), and 244 had 
MPN (98 with MPE, 136 without MPE, and 10 with unknown 
data for MPE). Characteristics of patients with pleural carci-
nomatosis were compared with those of patients without pleu-
ral carcinomatosis (Table 1). Elevation of preoperative serum 
tumor markers (including carcinoembryonic antigen, squa-
mous cell carcinoma-related antigen, cytokeratin 19 fragment, 
Sialyl Lewis X, neuron-specific enolase, and progastrin-releas-
ing peptide), nonsquamous cell carcinoma histology, larger 
tumor size, and lymph node involvement were significantly 
associated with a higher incidence of pleural carcinomatosis.
The treatment modalities are summarized in Table 2. 
To avoid any impact from another metastasis, we excluded 
16 patients with other M1a and/or M1b disease, and there-
fore, we analyzed 313 patients. Despite the presence of pleu-
ral carcinomatosis, the primary tumor was resected in 256 
(81.8%) patients. Even in the 81 patients diagnosed with or 
suspected to have pleural carcinomatosis before thoracotomy, 
the rate of primary tumor resection was similar, but the rate of 
pneumonectomy was significantly higher than that in patients 
who were diagnosed at thoracotomy. Postoperative chemo-
therapy before disease progression was used in 180 (57.5%) 
patients.
The median survival time (MST) and 5-year survival 
rate of all 313 patients were 34.0 months and 29.3%, respec-
tively. The 5-year survival rate for the 92 patients with both 
MPE and MPN was 16.2%, whereas the 5-year survival rates 
for the 81 patients only with MPE and the 126 patients only 
with MPN were 37.6% (p = 0.001) and 34.5% (p < 0.001), 
respectively (Fig. 1).
To identify prognostic factors, we performed univariate 
and multivariate analyses using the Cox proportional hazards 
model (Table 3). Univariate analyses revealed that women, 
Eastern Cooperative Oncology Group (ECOG) performance 
status of 0 to 1, adenocarcinoma histology, tumor size ≤ 3cm, 
best stage N status (N0 or N1), resection of primary tumor, 
and absence of gross residual tumor were associated with 
significantly longer survival. These variables were examined 
by multivariate analysis, and ECOG performance status (p 
< 0.001), best stage N status (p = 0.002), and the presence/
absence of gross residual tumor (p = 0.013) persisted as inde-
pendent predictors of survival.
The 5-year survival rate for patients with macroscopic 
complete resection was 37.1%, compared with 22.7% and 
12.2% in patients with macroscopic incomplete resection 
(p = 0.009) and exploratory thoracotomy (p < 0.001), respec-
tively (Fig. 2). There was no significant prognostic difference 
between macroscopic incomplete resection and exploratory 
thoracotomy (p = 0.137).
We also examined the clinicopathological variables of 
57 patients subjected to exploratory thoracotomy (Table 4). 
Although the proportion of patients with a large number of 
MPN was significantly higher in the exploratory thoracotomy 
group (52.6%, p = 0.007), 86 (33.6%) patients in the primary 
tumor resection group had a large number of MPN. By contrast, 
the proportion of patients with N2/N3 was significantly lower 
in the exploratory thoracotomy group (22.8%, p = 0.045).
DISCUSSION
The advantage of this study was that the sample was 
very large, and that the patients were treated at approximately 
the same time. According to a recent systematic review of 
pleural carcinomatosis studies, the number of patients ranged 
from 5 to 227, and the study duration ranged from 4 to 17 
years.2 Our study had more than 300 patients, and all of them 
underwent thoracotomy in 2004. The short-term study enables 
us to eliminate the effect of progress in chemotherapy, diag-
nosis, etc.
In this study, we had 329 (2.9%) patients with pleural 
carcinomatosis, but the incidence was slightly lower than that 
in previous studies.6,14 Patients with a small amount of MPE 
may have blended in with the 217 patients with positive pleu-
ral lavage cytology in our registry. Because other metastases 
may have influenced the choice of therapy and the prognosis 
in patients with pleural carcinomatosis, the analyses of treat-
ment modalities and survival were performed for 313 patients 
without other M1a and/or M1b disease.
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It remains controversial whether MPE and MPN have 
the same disease state. Several studies have reported that 
there is no significant difference in survival between MPE and 
MPN,6,14 but Fukuse et al.7 demonstrated that MPE had a bet-
ter prognosis than MPN. We therefore first performed survival 
analysis of MPE and MPN. We found that although patients 
with both MPE and MPN had worse prognosis than patients 
with only MPE or MPN, there was no significant prognostic 
difference between MPE and MPN (Fig. 1). Subsequently, we 
analyzed MPE and MPN collectively.
In 2004, in Japan, the primary tumor was resected in 
256 of the 313 (81.8%) patients with pleural carcinomato-
sis who had undergone thoracotomy. The majority of the 
patients had undergone a standard operation, such as lobec-
tomy or pneumonectomy with regional lymph node dissec-
tion, and only 55 (17.6%) had undergone wedge resection. 
The fact that pleural carcinomatosis is often accompanied 
by lymph node involvement6,8,14,15 may have contributed to 
the decision to perform a standard operation. Surprisingly, 
of 81 patients diagnosed with or suspected to have pleural 
carcinomatosis before thoracotomy, 63 (77.8%) underwent 
primary tumor resection. In fact, these patients tended to 
have more advanced disease than patients diagnosed at tho-
racotomy. This included 6 (7.4%) patients with ECOG per-
formance status of 2 or 3, 52 (64.2%) with elevated serum 
tumor markers, 8 (9.9%) with massive MPE (≥ 300 mL), and 
41 (50.6%) with a large number of MPN. It is uncertain why 
thoracotomy was chosen for these patients. The develop-
ment of computed tomography has increased the chance of 
detecting smaller amounts of pleural effusion and/or a few 
subtle pleural nodules. In our data, there was no significant 
difference in survival between patients with pleural carcino-
matosis detected at thoracotomy and those detected before 
thoracotomy (Table 3). In fact, this was just an atypical result 
obtained retrospectively, though it may be suggested that the 
critical factor is not the detection method but the amount of 
effusion or the extent of dissemination.
Extent of MPNc
  Absence  82 (24.9)
  Small number 122 (37.1)
  Large number 122 (37.1)
  Unknown 3 (0.9)
Data are mean ± SD or number (%). Bold values indicate statistically significant.
aWe collected information about tumor markers including CEA, SCC, CYFRA, 
SLX, NSE, and proGRP.
bDescribed in 7th edition of tumor, node, metastasis classification.
cDescribed in 6th edition of the General Rule for Clinical and Pathological Record 
of Lung Cancer in Japan.
ECOG, Eastern Cooperative Oncology Group; SD, standard deviation; MPE, malignant 
pleural effusion; MPN, malignant pleural nodules; CEA, carcinoembryonic antigen; SCC, 
squamous cell carcinoma-related antigen; CYFRA, cytokeratin 19 fragment; SLX, Sialyl 
Lewis X; NSE, neuron-specific enolase; proGRP, progastrin releasing peptide.
TABLE 1. (Continued)
Patients 
with Pleural 
Carcinomatosis 
(n = 329)
Patients 
Without Pleural 
Carcinomatosis 
(n = 11,046) P Value
TABLE 1.  Demographic and Clinicopathological 
Characteristics of Patients
Patients 
with Pleural 
Carcinomatosis 
(n = 329)
Patients 
Without Pleural 
Carcinomatosis 
(n = 11,046) P Value
Age, years (mean ± SD) 66.4 ± 10.0 66.7 ± 9.9 0.583
Sex 0.093
  Male 191 (58.1) 6931 (62.7)
  Female 138 (41.9) 4115 (37.3)
ECOG performance status 0.283
  0 271 (82.4) 9109 (82.5)
  1 44 (13.4) 1595 (14.4)
  2 5 (1.5) 143 (1.3)
  3 3 (0.9) 30 (0.3)
  4 0 (0.0) 1 (0.0)
  Unknown 6 (1.8) 168 (1.5)
Serum tumor marker levela <0.001
  Normal 110 (33.4) 6074 (55.0)
  High 177 (53.8) 3999 (36.2)
  Unknown 42 (12.8) 973 (8.8)
Histology <0.001
  Adenocarcinoma 255 (77.5) 7640 (69.2)
  Squamous cell carcinoma 43 (13.1) 2543 (23.0)
  Large cell carcinoma 15 (4.5) 371 (3.4)
  Others 16 (4.9) 492 (4.4)
Clinical stageb <0.001
  IA 77 (23.4) 6073 (55.0)
  IB 65 (19.7) 2230 (20.2)
  IIA 23 (7.0) 766 (6.9)
  IIB 23 (7.0) 613 (5.5)
  IIIA 46 (14.0) 1132 (10.2)
  IIIB 2 (0.6) 84 (0.8)
  IV 93 (28.3) 148 (1.3)
 Tumor size, cm (mean ± SD) 3.8 ± 2.0 3.0 ± 1.9 <0.001
Best stage T statusb <0.001
  T1a 17 (5.2) 3488 (31.6)
  T1b 19 (5.8) 1993 (18.0)
  T2a 149 (45.3) 3641 (33.0)
  T2b 14 (4.2) 509 (4.6)
  T3 106 (32.2) 1233 (11.2)
  T4 24 (7.3) 182 (1.6)
Best stage N statusb <0.001
  N0 159 (48.3) 8585 (77.7)
  N1 53 (16.1) 823 (7.4)
  N2 112 (34.1) 1598 (14.5)
  N3 5 (1.5) 40 (0.4)
Extent of MPE
  Absence 136 (41.3)
  <300 mL 167 (50.8)
  ≥300 mL 16 (4.9)
  Unknown 10 (3.0)
(Continued)
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Kimura et al.16 reported that platinum-based chemo-
therapy is the mainstay of treatment for patients with pleural 
dissemination. Contrary to our prediction, the rate of adju-
vant chemotherapy was not very high (57.5%). The favorable 
efficacy of intrapleural chemotherapy including intraoperative 
intrapleural hypotonic cisplatin treatment has also been dem-
onstrated,15,17–19 but regrettably, we had no information about 
this therapy in our registry. This may explain the low rate of 
adjuvant chemotherapy.
In this study, the MST and 5-year survival rate of 
all 313 patients with pleural carcinomatosis were 34.0 
months and 29.3%, respectively. Ichinose et al.6 analyzed 
227 patients with pleural carcinomatosis diagnosed at tho-
racotomy in 1985–1994 and reported that the MST and 
5-year survival rate were 16.9 months and 14.0%, respec-
tively. Because their resection rate (85%) was similar to 
ours, improved survival is probably because of factors 
such as better patient selection with improved diagnos-
tic technologies and advances in chemotherapy including 
epidermal growth factor receptor (EGFR) tyrosine kinase 
inhibitors.
There was no particularly new finding about prognos-
tic factors. In the multivariate analysis, ECOG performance 
status, best stage N status, and the presence/absence of gross 
residual tumor remained independent predictors of survival 
(Table 3). The group with gross residual tumors was a mix-
ture of patients with and without primary tumor resection. We 
therefore performed a survival comparison between patients 
with macroscopic incomplete resection and exploratory tho-
racotomy. The survival curves were somewhat separated, but 
there was no significant difference between the two groups 
(p = 0.137, Fig. 2).
TABLE 2.  Treatment Modalities
Total  
(n = 313)
Diagnosed at Thoracotomy 
(n = 232)a
Diagnosed or Suspected 
before Thoracotmy (n = 81) P Value
Preoperative treatment
  Done 12 (3.8) 6 (2.6) 6 (7.4) 0.085
   Chemotherapy 9 (2.9) 4 (1.7) 5 (6.2)
   Radiotherapy 1 (0.3) 1 (0.4) 0 (0.0)
   Chemoradiotherapy 2 (0.6) 1 (0.4) 1 (1.2)
  None 301 (96.2) 226 (97.4) 75 (92.6)
Surgical treatment
  Primary tumor resection 256 (81.8) 193 (83.2) 63 (77.8) 0.316c
   Pneumonectomyb 21 (6.7) 9 (3.9) 12 (14.8) <0.001d
   Lobectomy/bilobectomy 165 (52.7) 133 (57.3) 32 (39.5)
   Segmentectomy 15 (4.8) 10 (4.3) 5 (6.2)
   Wedge-resection 55 (17.6) 41 (17.7) 14 (17.3)
  Exploratory thoracotomy 57 (18.2) 39 (16.8) 18 (22.2)
Postoperative adjuvant chemotherapy
  Done 180 (57.5) 130 (56.0) 50 (61.7) 0.590e
   Oral 24 (7.7) 17 (7.3) 7 (8.6)
   Intravenous 151 (48.2) 108 (46.6) 43 (53.1)
   Others 5 (1.6) 5 (2.1)
  None 113 (36.1) 85 (36.7) 28 (34.6)
  Unknown 20 (6.4) 17 (7.3) 3 (3.7)
Data are number (%). Bold values indicate statistically significant.
aIncludes one patient without information on preoperative diagnosis.
bIncludes extrapleural pneumonectomy.
cPrimary tumor resection versus exploratory thoracotomy.
dPneumonectomy versus the other primary tumor resection.
eDone versus none.
FIGURE 1.  Overall survivals according to status of pleural 
carcinomatosis. MPE, malignant pleural effusion; MPN, malig-
nant pleural nodules.
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Several previous studies also demonstrated that primary 
tumor resection was associated with better prognosis in patients 
with pleural carcinomatosis diagnosed at thoracotomy.6–11 It 
seems reasonable to assume that selection bias may influence 
the results, and therefore, we compared the clinicopathologi-
cal features between the exploratory thoracotomy group and the 
primary tumor resection group in our cohort (Table 4). Although 
MPN subclassification (D1: small number/D2: large number) 
TABLE 3.  Univariate and Multivariate Analyses of Prognostic Factors by Using Cox Proportional Hazards Model
Variables n (%)
Univariate Analysis Multivariate Analysis
Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
Age 0.127
  <70 166 (53.0) 1
  ≥70 147 (47.0) 1.237 (0.941–1.627)
Sex 0.024 0.150
  Male 179 (57.2) 1 1
  Female 134 (42.8) 0.726 (0.550–0.958) 0.805 (0.599–1.082)
ECOG performance statusa <0.001 <0.001
  0–1 300 (95.8) 1 1
  2–3 7 (2.2) 20.756 (8.556–50.351) 13.856 (5.568–34.479)
Serum tumor marker levela,b 0.904
  Normal 107 (34.2) 1
  High 165 (52.7) 1.019 (0.756–1.372)
Histology 0.002 0.122
  Adenocarcinoma 246 (78.6) 1 1
  Others 67 (21.4) 1.664 (1.203–2.301) 1.328 (0.927–1.902)
Preoperative diagnosis of pleural 
carcinomatosisa
0.076
  Absent 231 (73.8) 1
  Presentc 81 (25.9) 1.321 (0.971–1.797)
Maximum tumor size 0.003 0.097
  ≤3 cm 132 (42.2) 1 1
  >3 cm 181 (57.8) 1.530 (1.155–2.028) 1.290 (0.955–1.743)
Best stage N status 0.004 0.002
  N0/N1 204 (65.2) 1 1
  N2/N3 109 (34.8) 1.500 (1.135–1.983) 1.585 (1.177–2.135)
Presence of malignant pleural 
effusiona
0.061
  No 128 (40.9) 1
  Yes 175 (55.9) 1.315 (0.988–1.749)
Presence of MPNa 0.075
  No 81 (25.9) 1
  Yes 230 (73.5) 1.346 (0.970–1.868)
Resection of primary tumor 0.001 0.089
  No 57 (18.2) 1 1
  Yes 256 (81.8) 0.573 (0.411–0.798) 0.714 (0.484–1.052)
Gross residual tumor a <0.001 0.013
  Absence 152 (48.6) 1 1
  Presence 147 (47.0) 1.691 (1.273–2.246) 1.530 (1.094–2.140)
Postoperative chemotherapya 0.548
  No 113 (36.1) 1
  Yes 175 (55.9) 0.916 (0.688–1.219)
Bold values indicate statistically significant.
aMissing category not shown.
bWe collected information about tumor markers including CEA, SCC, CYFRA, SLX, NSE, and proGRP.
cIncludes suspicion of pleural carcinomatosis.
ECOG, Eastern Cooperative Oncology Group; CI, confidence interval; CEA, carcinoembryonic antigen; SCC, squamous cell carcinoma-related antigen; CYFRA, cytokeratin 19 
fragment; MPN, malignant pleural nodules; SLX, Sialyl Lewis X; NSE, neuron-specific enolase; proGRP, progastrin releasing peptide.
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was abolished in the 7th edition of the General Rule for Clinical 
and Pathological Record of Lung Cancer in Japan20 because 
of ambiguous definitions, certain trends could be found. The 
proportion of patients with a large number of MPN was sig-
nificantly higher in the exploratory thoracotomy group. This 
indicated that patients with relatively localized MPN tended to 
be selected for resection. We cannot deny the possibility that 
the status of pleural carcinomatosis would affect prognosis, but 
there was no significant survival difference between D0 and D1, 
2 (Table 3). On the other hand, lymph node involvement was 
more advanced in the resection group. We suspected that this 
was because the nodal status in patients with primary tumor 
resection was mostly determined pathologically but in patients 
with exploratory thoracotomy was usually determined clini-
cally. But even in such situation, it is a fact that best stage N sta-
tus is an independent predictor of survival. Thus, patients with 
favorable prognosis were not necessarily selected.
Recently, EGFR mutations are regarded as an impor-
tant factor in predicting survival outcomes.21,22 As adenocar-
cinoma is dominant in patients with pleural carcinomatosis, 
EGFR mutation is clinically meaningful in this category, 
but we could not obtain any genetic information from our 
database. Although there was only indirect proof of EGFR 
mutation, there were no significant differences in gender, 
smoking history, and histological type between the explor-
atory thoracotomy group and the primary tumor resection 
group.
Although primary tumor resection was frequently per-
formed for patients with pleural carcinomatosis in 2004, at that 
time MPE and/or MPN were still classified as T4. Currently, 
they have been reclassified as M1a; therefore, it will be very 
interesting to note changes in the resection rate.
Our study has some limitations. First, because this is 
a retrospective study of surgical cases, patients included in 
this analysis were highly selected and not representative of 
all patients with pleural carcinomatosis. Second, because our 
data set was not specific for pleural carcinomatosis, interest-
ing information, such as the administration of intraoperative 
FIGURE 2.  Overall survivals according to presence/absence 
of gross residual tumor and primary tumor resection. Patients 
with missing data on gross residual tumor (n = 14) were 
excluded. MCR, macroscopic complete resection; MIR, mac-
roscopic incomplete resection; ET, exploratory thoracotomy.
TABLE 4.  Comparison of Clinicopathological Characteristics 
and Postoperative Treatment Between Patients with 
Exploratory Thoracotomy and Primary Tumor Resection
Variables
Patients Who 
Underwent 
Exploratory 
Thoracotomy 
(n = 57)
Patients Who 
Underwent 
Primary Tumor 
Resection  
(n = 256) P Value
Age 0.380
  <70 27 (47.4) 139 (54.3)
  ≥70 30 (52.6) 117 (45.7)
Sex
  Male 33 (57.9) 146 (57.0) 1.000
  Female 24 (42.1) 110 (43.0)
ECOG performance status 0.618
  0–1 55 (96.5) 245 (95.7)
  2–3 2 (3.5) 5 (2.0)
  Unknown 0 (0.0) 6 (2.3)
Smoking history 0.538
  Absence 25 (43.9) 107 (41.8)
  Presence 26 (45.6) 137 (53.5)
  Unknown 6 (10.5) 12 (4.7)
Histology 0.725
  Adenocarcinoma 46 (80.7) 200 (78.1)
  Others 11 (19.3) 56 (21.9)
Best stage T status 0.459
  T1/T2 37 (64.9) 152 (59.4)
  T3/T4 20 (35.1) 104 (40.6)
Best stage N status 0.045
  N0/N1 44 (77.2) 160 (62.5)
  N2/N3 13 (22.8) 96 (37.5)
Extent of MPE 0.122
  Absence 22 (38.6) 106 (41.4)
  <300 mL 26 (45.6) 136 (53.1)
  ≥300 mL 5 (8.8) 8 (3.1)
  Unknown 4 (7.0) 6 (2.3)
Extent of MPNb 0.007
  Absence 7 (12.3) 74 (28.9)
  Small number 19 (33.3) 95 (37.1)
  Large number 30 (52.6) 86 (33.6)
  Unknown 1 (1.8) 1 (0.4)
Postoperative adjuvant chemotherapy 1.000a
  Done 33 (57.9) 147 (57.4)
   Oral 3 (5.3) 21 (8.2)
   Intravenous 30 (52.6) 121 (47.3)
   Others 0 (0.0) 5 (2.0)
  None 21 (36.8) 92 (35.9)
  Unknown 3 (5.3) 17 (6.6)
Data are number (%). Bold values indicate statistically significant.
aDone versus none.
bDescribed in 6th edition of the General Rule for Clinical and Pathological Record 
of Lung Cancer in Japan.
ECOG, Eastern Cooperative Oncology Group; MPE, malignant pleural effusion; 
MPN, malignant pleural nodules.
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intrapleural chemotherapy, EGFR mutation status, and sites of 
relapse, was lacking.
Because of these limitations, the question whether sur-
gical resection should be performed for patients with pleural 
carcinomatosis remains unanswered. However, in our surgical 
registry for NSCLC patients, macroscopic complete resection 
was associated with better survival.
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